IRLAB Therapeutics (IRLAB) Q2 2025 earnings summary

Executive summary

• Achieved key milestones in drug development, including positive Phase I results for IRL757 and a new US patent for mesdopetam, extending exclusivity into the mid-2040s and strengthening the intellectual property portfolio.

• Rights issue raised SEK 115.7 million before costs, significantly strengthening the financial position, with expanded loan agreements.

• Focused on advancing partnerships and licensing agreements to realize commercial value from the drug portfolio.

• Leadership transition with a new interim CFO appointed.

• Presented data at AD/PD conferences supporting the use of cortical enhancers in Parkinson's disease.

Financial highlights

• Net sales for H1 2025 were SEK 23.9 million, down from SEK 42.8 million year-over-year.

• Operating loss widened to SEK -54.4 million from SEK -42.7 million year-over-year.

• Earnings per share before and after dilution were SEK -1.28, compared to SEK -0.89 in the prior year.

• Cash and cash equivalents at period end were SEK 54 million, with an additional SEK 56 million from the rights issue to be added in Q3.

• Equity turned negative at SEK -27.7 million, compared to SEK 69.7 million a year earlier.

Outlook and guidance

• Phase III program initiation for mesdopetam is a key milestone in the next 12-18 months.

• Preparing for a Phase Ib study with IRL757 in Parkinson’s patients with apathy, with first patient recruitment expected in Q4 2025.

• Decision on next steps for pirepemat, including dose optimization study, is expected.

• Ongoing efforts to secure revenue-generating partnerships and licensing deals for advanced drug candidates.

• IRL942 and IRL1117: Preclinical development ongoing, with Phase I studies planned for 2026 and beyond.